ASMB Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
3.0M
-77.9%
13.4M
+62.8%
8.2M
-80.7%
42.5M
+293.6%
10.8M
Cost of Revenue
0
0
0
0
0
Gross Profit
3.0M
-77.9%
13.4M
+62.8%
8.2M
-80.7%
42.5M
+293.6%
10.8M
Operating Expenses
26.4M
+33.7%
19.7M
+0.7%
19.6M
-13.6%
22.7M
+4.6%
21.7M
R&D
20.2M
+35.6%
14.9M
+0.1%
14.9M
-13.6%
17.3M
+4.0%
16.6M
SG&A
6.1M
+27.8%
4.8M
+2.5%
4.7M
-13.6%
5.4M
+6.6%
5.1M
Operating Income
-23415000
-269.1%
-6344000
+44.2%
-11370000
-157.4%
19.8M
+281.9%
-10883000
EBITDA
-23391000
-269.9%
-6324000
+44.3%
-11344000
-157.2%
19.8M
+282.8%
-10851000
Net Income
-20256000
-425.2%
-3857000
+57.5%
-9079000
-141.1%
22.1M
+340.2%
-9196000
EPS (Basic)
$-0.93
-365.0%
$-0.20
+63.0%
$-0.54
-141.5%
$1.30
+280.6%
$-0.72
EPS (Diluted)
$-0.93
-365.0%
$-0.20
+63.0%
$-0.54
-141.5%
$1.30
+280.6%
$-0.72
Shares (Diluted)
21.8M
+15.5%
18.9M
+11.6%
16.9M
-0.6%
17.0M
+34.0%
12.7M
Assembly Biosciences (ASMB) — Financials